Jeffrey Leiden is executive chairman of Vertex Pharmaceuticals, having devoted his career to improving the lives of people with serious diseases.
Leiden previously served as Vertex’s president, chief executive and chairman from 2012 until March 2020. He has also been a member of the company’s board since July 2009.
During his leadership, Vertex developed Kalydeco, Orkambi and Trikafta, described as the first and only medicines to treat the underlying cause of cystic fibrosis in patients with certain forms of the disease.
Alongside his role at Vertex, Leiden is lead independent director of Massachusetts Mutual Life Insurance Company, chairman of Odyssey Therapeutics and chairman of Casana.
He is a member of the MIT CEO Advisory Board and a director of the Massachusetts Competitive Partnership. He also serves on the Massachusetts Governor’s Digital Healthcare Council, the Governor’s Task Force on Artificial Intelligence and the Governor’s STEM Advisory Council.
Leiden received his BA, MD and PhD degrees from the University of Chicago.
